Table 1 Protocol of four drug regimens for health economic evaluation in Thai HIV transmission cost-effectiveness model
Code | Drug regimens | Zidovudine (AZT) | Nevirapine (NVP) | ||
|---|---|---|---|---|---|
mother | infant | mother | infant | ||
A | A short course AZT (practice in Thailand to 2004) | Starting from 32–34 week of gestation onward + intrapartum doses | From birth for 7 days (6 weeks in the case of the mother receiving <4 weeks AZT) | Not provided | Not provided |
B | NVP alone (never adopted in the national policy) | Not provide | Not provide | Intrapartum single dose | Single dose after delivery |
C | AZT or NVP (never adopted in the national policy) | Start at 32 but not latter than 34 weeks of gestations + intrapartum doses but not with NVP | From birth for 7 days (6 weeks in the case of the mother receiving <4 weeks AZT) – and given only the cases that mother received AZT | If mother know HIV status after 34 weeks then give single dose but not with AZT | Single dose after delivery if mother received NVP only |
D | AZT and NVP (current practice, commencing from 2004) | Starting from 28 week of gestation onward + intrapartum doses | From birth for 7 days (6 weeks in the case of the mother receiving <4 weeks AZT) | In trapartum single dose | Single dose after delivery |